157 related articles for article (PubMed ID: 9736584)
1. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.
García-Garrote F; Cercenado E; Alcalá L; Bouza E
Antimicrob Agents Chemother; 1998 Sep; 42(9):2452-5. PubMed ID: 9736584
[TBL] [Abstract][Full Text] [Related]
2. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
4. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.
Cercenado E; García-Garrote F; Bouza E
J Antimicrob Chemother; 2001 Jan; 47(1):77-81. PubMed ID: 11152434
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
Zeckel ML; Preston DA; Allen BS
Antimicrob Agents Chemother; 2000 May; 44(5):1370-4. PubMed ID: 10770782
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
[TBL] [Abstract][Full Text] [Related]
9. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Kirk M; Hill RL; Casewell MW; Beighton D
Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
[No Abstract] [Full Text] [Related]
10. [Antimicrobial spectrum of dalbavancin. Mechanism of action and in vitro activity against Gram-positive microorganisms].
Cercenado E
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():9-14. PubMed ID: 28129822
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
Jones RN; Barrett MS; Erwin ME
Antimicrob Agents Chemother; 1997 Feb; 41(2):488-93. PubMed ID: 9021216
[TBL] [Abstract][Full Text] [Related]
12. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
al-Nawas B; Shah PM
Infection; 1998; 26(3):165-7. PubMed ID: 9646108
[TBL] [Abstract][Full Text] [Related]
13. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
14. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
Al-Nawas B; Swantes J; Shah PM
Infection; 2000; 28(4):214-8. PubMed ID: 10961526
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci.
Noviello S; Ianniello F; Esposito S
J Antimicrob Chemother; 2001 Aug; 48(2):283-6. PubMed ID: 11481302
[TBL] [Abstract][Full Text] [Related]
17. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of LY 333328 against anaerobic gram-positive bacteria.
Sillerström E; Wahlund E; Nord CE
J Chemother; 1999 Apr; 11(2):90-2. PubMed ID: 10326737
[TBL] [Abstract][Full Text] [Related]
19. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
[TBL] [Abstract][Full Text] [Related]
20. Glycopeptide antibiotics: from conventional molecules to new derivatives.
Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]